Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dermtech Inc (NQ: DMTK )

1.700 +0.010 (+0.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dermtech Inc

< Previous 1 2 3 4 Next >
DermTech to Present at March Investor Conferences
From DermTech, Inc.
Via Business Wire
DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan
From DermTech, Inc.
Via Business Wire
DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE
From DermTech, Inc.
Via Business Wire
DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test
From DermTech, Inc.
Via Business Wire
DermTech Reports Third-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Announces Release Date for Third-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 Outlook
From DermTech, Inc.
Via Business Wire
DermTech Appoints Chief Compliance Officer and SVP of Research and Development
From DermTech, Inc.
Via Business Wire
DermTech Announces Release Date for Second-Quarter 2022 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech Appoints Two New Board Members
From DermTech, Inc.
Via Business Wire
DermTech Joins PeDRA Corporate Council, Supporting Efforts to Address Pediatric Skin Diseases
From DermTech, Inc.
Via Business Wire
DermTech to Present on Genomic Innovation in Dermatology at AHIP 2022
From DermTech, Inc.
Via Business Wire
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DermTech, Inc.
Via Business Wire
DermTech to Present at the William Blair Growth Stock Conference
From DermTech, Inc.
Via Business Wire
DermTech Sponsors The Sun Bus to Bring Free Skin Cancer Screenings to More Than 50 Locations Across the U.S.
From DermTech, Inc.
Via Business Wire
DermTech Presents New Research Differentiating Atopic Dermatitis and Psoriasis at the Society for Investigative Dermatology’s Annual Meeting
From DermTech, Inc.
Via Business Wire
DermTech Reinforces Longstanding Mission to Help Reduce Melanoma Deaths, Aligning with the Biden Administration’s Renewed ‘Cancer Moonshot’ Program
From DermTech, Inc.
Via Business Wire
DermTech Kicks Off Second Annual #Stickit2Melanoma Campaign, Raising Awareness for Melanoma and the Importance of Skin Exams
From DermTech
Via Business Wire
DermTech Reports First-Quarter 2022 Financial Results; Company Affirms Full-Year 2022 Outlook
From DermTech, Inc.
Via Business Wire
DermTech Announces Publication of New GvHD Clinical Research Conducted in Collaboration with Memorial Sloan Kettering Cancer Center
From DermTech, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.